FindTrial
Sign In

The study for simeprevir, peg-interferon, and ribavirin treatment efficacy against the patients with chronic hepatitis C (Multicenter trial)

The study for simeprevir, peg-interferon, and ribavirin treatment efficacy against the patients with chronic hepatitis C (Multicenter trial) - The study for simeprevir, peg-interferon, and ribavirin treatment efficacy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017654
Enrollment
200
Registered
2015-05-22
Start date
2014-01-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

administration of peg-interferon alfa-2a 180ug/week for 24 weeks administration of peg-interferon alfa-2b 1.5ug/kg/week for 24 weeks

Sponsors

Shinanomachi Liver Conference
Lead Sponsor
EIJU General Hospital Kitasato Institute Hospital Saitama Social Insurance Hospital Saiseikai Central Hospital National Hospital Organization Tokyo Medical Center Saiseikai Utsunomiya Hospital Japanese Red Cross Mito Hospital Yokohama Municipal Citizen&#39
Collaborator
s Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with chronic hepatitis C

Exclusion criteria

Exclusion criteria: Patients who were thought to be unsuitable

Design outcomes

Primary

MeasureTime frame
sustained virological response rate—

Secondary

MeasureTime frame
peg-interferon alfa-2a or alfa-2b—

Countries

Japan

Contacts

Public ContactHirotoshi Ebinuma

Keio University, School of Medicine Division of Gastroenterology & Hepatology

ebinuma@a5.keio.jp03-3353-1211-62384

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026